What's Happening?
A systematic review published in The Canadian Journal of Psychiatry suggests that creatine monohydrate, a supplement commonly used by athletes, may benefit individuals with major depressive disorder. The review analyzed five randomized controlled trials
involving 238 participants and found that creatine supplementation, when added to standard treatments like antidepressants or talk therapy, improved depressive symptoms. The supplement, which plays a role in cellular energy management, showed potential in enhancing brain energy metabolism, a factor linked to mood disorders.
Why It's Important?
The findings offer a potential new avenue for managing major depressive disorder, particularly for patients who do not fully respond to traditional treatments. Creatine's accessibility and safety profile make it an attractive option for supplementing psychiatric care. This research could lead to broader acceptance of dietary supplements in mental health treatment, providing additional tools for clinicians to address mood disorders. However, the review also highlights the need for further studies to confirm these benefits and determine optimal dosing strategies.
What's Next?
Future research should focus on larger, long-term studies to better understand creatine's effects on mental health. Scientists are encouraged to explore higher doses and combinations with other interventions, such as physical exercise, to maximize benefits. The potential for creatine to support brain health in other psychiatric conditions, beyond major depressive disorder, also warrants investigation. As the evidence base grows, creatine could become a more widely recommended supplement in mental health care.
